$218.89
CME Group is a financial data & stock exchanges business based in the US. CME Group shares (CME.US) are listed on the NASDAQ and all prices are listed in US dollars. Its last market close was $217.50 – a decrease of 0.87% over the previous day. CME Group employs 3,565 staff and has a trailing 12-month revenue of around $5.6 billion.
How to buy shares in CME Group
- Choose a platform. If you're a beginner, our stock trading platform picks below can help you choose.
- Open your account. Provide your personal information and sign up.
- Confirm your payment details. You'll need to fund your account with a bank transfer, debit card or credit card.
- Search the platform for stock code: CME in this case.
- Research stocks. The platform should provide the latest information available.
- Buy your stocks. Place a market order or limit order with your preferred number of shares. It's that simple.
Our top picks for buying CME Group stock
- Trade options, futures, options on futures, stocks, ETFs
- $0 commission to close options
- Get $100-$5,000 when you open an account with $5,000 to $1,000,000+
- Earn up to 3% in matching funds on Robinhood IRA contributions
- Earn up to 5.25% interest on uninvested cash
- Get a free stock when you successfully sign up and link your bank account
- Trade fractional shares of stocks, ETFs and Bitcoin
- Invest with as little as $1
- Free to open, no minimum balance required and no commission fees
Is it a good time to buy CME Group stock?
Only you can make the decision on the time to leap... but here's some supporting information and analysis.
Share price volatility
Over the last 12 months, CME Group's shares have ranged in value from as little as $167.7288 up to $221.4646. A popular way to gauge a stock's volatility is its "beta".
Beta is a measure of a share's volatility in relation to the market. The market (NASDAQ average) beta is 1, while CME Group's is 0.498. This would suggest that CME Group's shares are less volatile than average (for this exchange).
Historical closes compared with the last close of $217.5
1 week (2024-03-11) | -0.11% |
---|---|
1 month (2024-02-15) | 2.47% |
3 months (2023-12-17) | 2.99% |
6 months (2023-09-18) | 5.34% |
1 year (2023-03-12) | 21.03% |
2 years (2022-03-15) | -10.13% |
3 years (2021-03-18) | 7.32% |
5 years (2019-03-18) | 28.90% |
The gauge below shows real-time ratings that are based on 26 popular indicators such as moving averages, for specific time periods. It's not a recommendation but is simply technical analysis that can form part of your research.
Finder might not agree with the analysis and we take no responsibility. We also give no representations or warranty on the accuracy or completeness of the information provided on this page.
Buy CME Group stock from these online trading platforms
Compare special offers, low fees and a wide range of investment options among top trading platforms.Paid non-client promotion. Finder does not invest money with providers on this page. If a brand is a referral partner, we're paid when you click or tap through to, open an account with or provide your contact information to the provider. Partnerships are not a recommendation for you to invest with any one company. Learn more about how we make money.
Finder is not an adviser or brokerage service. Information on this page is for educational purposes only and not a recommendation to invest with any one company, trade specific stocks or fund specific investments. All editorial opinions are our own.
Is CME Group under- or over-valued?
Valuing a stock is incredibly difficult, and any metric has to be viewed as part of a bigger picture of overall performance. However, analysts commonly use some key metrics to help gauge value. Check out the CME Group P/E ratio, PEG ratio and EBITDA
CME Group's current stock price divided by its per-share earnings (EPS) over a 12-month period gives a "trailing price/earnings ratio" of roughly 25x. In other words, CME Group stocks trade at around 25x recent earnings.
That's relatively high compared to, say, the trailing 12-month P/E ratio for the United States stock markets on average as of November 09, 2023 (20.44). The high P/E ratio could mean that investors are optimistic about the outlook for the shares or simply that they're over-valued.
CME Group's "price/earnings-to-growth ratio" can be calculated by dividing its P/E ratio by its growth – to give 8.8567. Higher PEG ratios such as this can be interpreted as meaning the shares offer worse value given the current rate of growth.
The PEG ratio provides a broader view than just the P/E ratio, as it gives more insight into CME Group's future profitability. By accounting for growth, it could also help you if you're comparing the stock prices of multiple high-growth companies.
CME Group's EBITDA (earnings before interest, taxes, depreciation and amortisation) is a whopping $3.8 billion.
The EBITDA is a measure of a CME Group's overall financial performance and is widely used to measure a its profitability.
Frequently asked questions
More guides on Finder
-
10 best brokerage account bonuses of 2024
Explore the best bonuses for opening a new brokerage account.
-
11 best trading platforms for beginners 2024
These are the best trading platforms for beginners, according to Finder’s comprehensive analysis.
-
5 best international stock brokers of 2024
Want to buy and sell international stocks? Here are the top brokers to help you trade global markets.
-
5 best stock picking services of 2024
Compare the 5 best stock picking services, according to Finder’s analysis, and learn how to choose the best option for your needs.
-
Cash App Investing review 2024
Finder’s Cash App review covers fees, features and feedback to consider before you invest.
-
Methodology for online brokers
Our star ratings for online brokerages are based on how they stack up in nine key categories.
-
How to invest in the S&P 500 in 2024
What you need to know about investing in the leading indicator for the overall US stock market.
-
E-Trade review 2024
Take advantage of commission-free trading with stocks, ETFs and options with a flexible trading platform.
-
Webull review 2024
Webull is a broker with zero-commission trading and a suite of tools to help you invest.
-
Acorns review 2024
Acorns is a financial service that rounds up your purchases and turns the extra change into investments.
Ask an Expert